Core Viewpoint - The collaboration between AstraZeneca and Alibaba Health aims to fully promote the electronicization of key documents in the pharmaceutical supply chain, enhancing efficiency and sustainability [2][3]. Group 1: Electronicization Initiative - AstraZeneca and Alibaba Health held a launch ceremony for the electronicization of drug inspection reports and initial operating materials, marking a significant step towards a digital pharmaceutical supply chain [2]. - The current reliance on paper-based inspection reports leads to long transmission cycles, high storage costs, and risks of loss or damage, which the electronicization aims to address [2]. - Electronic circulation of drug inspection reports is expected to reduce operational costs related to manpower, logistics, and document management, while also mitigating regulatory risks associated with incomplete paper documents [2]. Group 2: Collaboration and Impact - AstraZeneca's Vice President highlighted that electronic documentation is crucial for achieving transparency in the pharmaceutical supply chain, improving operational efficiency, and reducing carbon emissions [2]. - Alibaba Health's Vice President stated that the "Code on Trust" platform has connected over 2,000 pharmaceutical manufacturers and nearly 10,000 distribution and logistics companies, facilitating efficient and traceable electronic circulation of drug inspection reports [3]. - The initiative also extends to the electronic exchange of initial operating materials and supply chain collaboration, contributing to the industry's green and low-carbon transformation [3].